

Requisitioning a resolution at a GSK Annual General Meeting







Requisitioning a resolution


There are occasions when shareholders may wish to draw important matters to the attention of other shareholders by proposing a resolution to be put to an Annual General Meeting (AGM).

The procedure for requisitioning a resolution is governed by English common law and statute. This specifies that unless a requisition is validly received before the end of the financial year preceding the meeting a company's costs in complying with a requisition are to be met by requisitionists. The funds to cover such costs must be deposited with the company before a requisition can be actioned. GSK has estimated that the cost of complying with a requisition may be as high as £200,000.

At GSK's AGM in May 2005 the Articles of Association were amended to remove the requirement for requisitionists to pay a deposit by authorising GSK to meet its own costs in complying with a valid requisition, provided that the requisition is received by 31 January each year.


Requisitionists who lodge a requisition after 31 January, but before the UK legal deadline of 6 weeks prior to the AGM, would, however, be required to pay a deposit and to meet GSK's costs of complying with the requisition. Requisitionists would, however, be free to include a supplementary resolution to request that GSK pays its own costs in complying with the requisition.

Shareholders wishing to requisition a resolution may find the following information helpful, but should in any event seek their own independent legal advice. A glossary of terms is set out at the end of this booklet.



Index

Requisitioning a resolution	. 3
Eligibility of members to requisition a resolution Eligibility of indirect investors to requisition a resolution Nominees	. 5
American Depository Receipts (ADR) holders	. 6
The requisition	. 7
The costs of actioning a requisition	. 8
Lodging a requisition	9
For a GSK AGM	
Key dates for 2012	. 10
Contact details	. 11
Glossary of terms	. 11



Requisitioning a resolution

To ensure there is no question of a member or indirect investor with a small shareholding requisitioning a resolution without sufficient support from other members or indirect investors, UK law sets out minimum shareholding requirements before a requisition can be made.

For a requisition involving only shareholders whose shares are registered directly in their own name (members), a requisition must be supported by the following in order to be valid:

either

 not less than 100 members holding shares on which there has been paid up an average sum per member of not less than £100;


or

 members representing not less than 5% of the total voting rights of all the members.


For indirect investors whose shares are held via a nominee or for GSK American Depository Receipts (ADR) holders, a requisition must be supported by the following in order to be valid:

 not less than 100 persons holding shares directly or indirectly on which there has been paid up an average sum per person of not less than £100.

The charts on pages 4 and 5 illustrate the implications of this requirement for GSK members and indirect investors.




Eligibility of members to requisition a resolution




PLEASE NOTE:

If your GSK shares are not registered in your own name or you hold GSK ADRs then you should refer to page 6 which explains how you should proceed.




Eligibility of indirect investors to requisition a resolution



PLEASE NOTE:

If your GSK shares are not registered in your own name or you hold GSK ADRs then you should refer to page 6 which explains how you should proceed.



Nominees

Indirect investors holding GSK Ordinary Shares via a nominee may submit a requisition provided that the requisition is:

- submitted by at least 100 persons with an average of £100 of paid up share capital each and authenticated by all the persons making it
- accompanied by a statement from the nominee or underlying shareholder(s) making the request, setting out the basis on which the GSK shares are being held by them/ for them. More details about this statement are set out on page 7.

Please note any costs associated with implementing these arrangements will not be met by GSK.

ADR holders

ADR holders – holders of record with The Bank of New York Mellon (BNYM)

ADR holders who hold their ADRs directly with GSK's ADR Depositary, BNYM, may submit a requisition through BNYM provided that the requisition is:

- submitted by at least 100 persons with an average of £100 of paid up share capital each and authenticated by all the persons making it
 - and
- accompanied by a statement from BNYM or the underlying ADR holder(s) making the request setting out the basis on which ADRs are being held by them/for them.

ADR holders – holding via a broker, nominee or other institution

ADR holders who do not hold their ADRs via BNYM may submit a requisition provided that it is:

- submitted by at least 100 persons with an average of £100 of paid up share capital each and authenticated by all the persons making it
 - and
- accompanied by a statement from the relevant broker, nominee or other institution through which the ADRs are held, or the underlying ADR holder(s) making the request, setting out the basis on which ADRs are being held by them/for them.


Please note any costs associated with implementing these arrangements will not be met by GSK.

BNYM may be contacted at:

The Bank of New York Mellon PO Box 358516 Pittsburgh PA 15252-8516

www.bnymellon.com/shareowner

Tel: 1 877 353 1154 (US toll free) Tel: +1 201 680 6825 (outside USA) email: shrrelations@bnymellon.com



The requisition

Requisitionists are strongly recommended to seek independent legal advice on the drafting of their requisition. Please note that GSK will not meet the requisitionists' legal or other costs in preparing a requisition.

Points to note:

- The requisition should be in English and in a readable form
- It may be in hard copy or electronic form.
- The resolution being proposed should be capable of being put to a general meeting and should not be defamatory, frivolous or vexatious.
- Where it is being submitted by members the requisition should be signed by all the persons making it, specifying for each member their full name, registered address, account number and the number of GSK Ordinary Shares they hold.
- Where a requisition is being submitted by an ADR holder the requisition should be accompanied by a statement setting out the name and address of the registered holder, the number of shares/ADRs held and the basis on which the shares/ADRs are being held.
- Where a requisition for a resolution is being supported by indirect investors as part of the 100 persons requirement (as set out on page 4) the requisition must be signed by all the persons making it and be accompanied by a statement for each indirect investor which includes the following:
 - the name and address of the registered member who holds the shares on their behalf;
 - confirmation that the member is holding those shares on their behalf in the course of business;
 - details of the number of shares held on their behalf and the total amount paid up on those shares;


- confirmation that those shares are not held by the member on behalf of anyone else or, if they are, that such other persons are not involved in the requisition;
- confirmation that at least some of the shares confer voting rights; and
- confirmation that they have the right to instruct the member on how to exercise those voting rights.

If any of the 100 persons is a member, the requisition must also be accompanied by a statement for each such member specifying that they hold shares otherwise than on behalf of another person or that they hold shares on behalf of one or more other persons but those persons are not involved in the requisition. This statement should also specify for each member the total amount paid up on the shares held as mentioned in the previous sentence.

GSK may also require that the supporting statements are accompanied with such evidence of the above matters which it may reasonably require.

These requirements also apply where indirect investors support a 100 persons requisition for the circulation of an explanatory statement (see immediately below).

The proposed resolution may be accompanied by an explanatory statement of not more than 1,000 (one thousand) words, which should also be signed by each of the requisitionists. The resolution, and where supplied an accompanying statement, will be issued on behalf of the requisitionists without giving their names. A specific request should be made for each requisitionist's name to be published. When complying with such a request, space constraints may require that a full list of these names be set out in an appendix to the Notice of Meeting.




The costs of actioning a requisition

UK law specifies that the burden of a company's costs in complying with a requisition falls on the requisitionists unless a requisition is validly received before the end of the financial year preceding the AGM, ie. 31 December for GSK.

Points to note:

- GSK has extended this deadline to 31 January. Therefore, unless a requisition is validly received by this date, the requisitionists are required by law to deposit with GSK a sum reasonably sufficient to meet GSK's expenses in giving effect to a requisition.
- It is estimated that the cost of requisitioning a resolution could be as high as £200,000, based on approximately 200,000 current shareholders. The actual costs of processing a requisition and accordingly the deposit required would be established at the time of receipt of a requisition.
- Requisitionists are entitled to include as part
 of their requisition a supplementary resolution
 for shareholders to authorise GSK to meet the
 costs of complying with the requisition.
 GSK would reimburse the amount deposited
 if the supplementary resolution is approved.



Lodging a requisition for a GSK AGM


GSK will meet its costs in complying with a requisition provided that a valid request is received by 31 January.

Requisitionists who lodge their requisition after that date will be required to deposit with the company sufficient funds to cover the costs in complying with the requisition and should consider including a supplementary resolution seeking approval for GSK to meet its own costs in complying with the requisition. If any supplementary resolution is passed allowing GSK to meet its own costs in complying with the requisition, GSK will refund the deposit within 10 working days of the AGM.

Please note that requisitionists will in any event have to meet their own costs in putting forward the requisition.

Requisition received:	Deposit required to meet the costs of complying with the requisition	Requisitionists required to meet the costs of complying with the requisition
Before 31 January	No	No
After 31 January	Yes	Yes*


^{*} NB – Requisitionists may submit a supplementary resolution to seek approval for GSK to meet its costs in complying with the requisition.



Key dates for GSK's 2012 AGM

Recommended submission date for member(s)/ADR holders wishing to requisition a resolution	Monday, 31 January 2012
Annual Report and AGM materials to be issued	Mid March 2012
UK legal deadline for member(s)/ADR holders wishing to requisition a resolution	Wednesday, 21 March 2012
2012 AGM	Thursday, 3 May 2012

These dates may be subject to change which will be posted on the website.



Contacts

If you wish to discuss any of these requirements then please contact:

Victoria Whyte Company Secretary GlaxoSmithKline plc 980 Great West Road Brentford Middlesex TW8 9GS

Tel: +44 (0)20 8047 5000

Glossary of Terms

Requisition – a formal request to a company from one or more of its members or indirect investors to put a resolution to an AGM.

Resolution – a proposal for members of a company to consider and decide upon.

ADR – an American Depositary Receipt representing two GSK Ordinary shares also referred to as an American Depositary Share.

BNYM – The Bank of New York Mellon, GSK's depositary bank which holds ADRs on behalf of investors.

Member – a shareholder whose name appears on the Register of Members, maintained by GSK's Registrar, Equiniti.

Indirect investor – a person on whose behalf a member holds GSK Ordinary Shares.